Outcome of Lenalidomide Treatment for Cognitive Impairment Caused by Immune Reconstitution Inflammatory Syndrome in Patients with HIV-Related Cryptococcal Meningitis

References

• Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873–881. doi:10.1016/S1473-3099(17)30243-8
   PubMed Web of Science ®Google Scholar
• Sitapati AM, Kao CL, Cachay ER, et al. Treatment of HIV-related inflammatory cerebral cryptococcoma with Adalimumab. Clin Infect Dis. 2010;50(2):e7–10. doi:10.1086/649553
   PubMed Web of Science ®Google Scholar
• Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis. 2010;10(11):791–802. doi:10.1016/S1473-3099(10)70170-5
   PubMed Web of Science ®Google Scholar
• Brienze VMS, Andre JC, Liso E, et al. Cryptococcal immune reconstitution inflammatory syndrome: from blood and cerebrospinal fluid biomarkers to treatment approaches. Life. 2021;11(2):95. doi:10.3390/life11020095
   PubMedGoogle Scholar
• Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13. doi:10.12703/P6-13
   PubMedGoogle Scholar
• Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med. 2010;7(12):e1000384. doi:10.1371/journal.pmed.1000384
   PubMed Web of Science ®Google Scholar
• Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33(4):289–294. doi:10.1097/00004836-200110000-00006
   PubMed Web of Science ®Google Scholar
• Musubire AK, Meya BD, Mayanja-Kizza H, et al. Challenges in diagnosis and management of Cryptococcal immune reconstitution inflammatory syndrome (IRIS) in resource limited settings. Afr Health Sci. 2012;12(2):226–230. doi:10.4314/ahs.v12i2.23
   PubMed Web of Science ®Google Scholar
• Brunel AS, Reynes J, Tuaillon E, et al. Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. AIDS. 2012;26(16):2110–2112. doi:10.1097/QAD.0b013e328358daea
   PubMed Web of Science ®Google Scholar
• Jung YJ, Tweedie D, Scerba MT, et al. Neuroinflammation as a factor of neurodegenerative disease: thalidomide analogs as treatments. Front Cell Dev Biol. 2019;7:313. doi:10.3389/fcell.2019.00313
   PubMed Web of Science ®Google Scholar
• Fourcade C, Mauboussin JM, Lechiche C, et al. Thalidomide in the treatment of immune reconstitution inflammatory syndrome in HIV patients with neurological tuberculosis. AIDS Patient Care STDS. 2014;28(11):567–569. doi:10.1089/apc.2014.0083
   PubMed Web of Science ®Google Scholar
• Dong RJ, Huang SZ, Upadhyay P, et al. Thalidomide in the treatment of sweet’s syndrome and eosinophilic folliculitis associated with immune reconstitution inflammatory syndrome. Front Med. 2019;6:343. doi:10.3389/fmed.2019.00343
   Web of Science ®Google Scholar
• Lortholary O, Fontanet A, Mémain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. Aids. 2005;19(10):1043–1049. doi:10.1097/01.aids.0000174450.70874.30
   PubMed Web of Science ®Google Scholar
• Vallet S, Palumbo A, Raje N, et al. Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma. 2008;49(7):1238–1245. doi:10.1080/10428190802005191
   PubMed Web of Science ®Google Scholar
• Dalla Torre C, Zambello R, Cacciavillani M, et al. Lenalidomide long-term neurotoxicity: clinical and neurophysiologic prospective study. Neurology. 2016;87(11):1161–1166. doi:10.1212/WNL.0000000000003093
   PubMed Web of Science ®Google Scholar
• Fine HA, Kim L, Albert PS, et al. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res. 2007;13(23):7101–7106. doi:10.1158/1078-0432.CCR-07-1546
   PubMed Web of Science ®Google Scholar
• Warren KE, Goldman S, Pollack IF, et al. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: pediatric brain tumor consortium study PBTC-018. J Clin Oncol. 2011;29(3):324–329. doi:10.1200/JCO.2010.31.3601
   PubMed Web of Science ®Google Scholar
• Li J, Huang XF, Cai QQ, et al. A prospective Phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Am J Hematol. 2018;93(6):803–809. doi:10.1002/ajh.25100
   PubMed Web of Science ®Google Scholar
• Denman J, Manavi K, Cook M. Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient. Int J STD AIDS. 2017;28(10):1045–1047. doi:10.1177/0956462417694561
   PubMed Web of Science ®Google Scholar
• Martinez V, Tateo M, Castilla MA, et al. Lenalidomide in treating AIDS-related Kaposi’s sarcoma. AIDS. 2011;25(6):878–880. doi:10.1097/QAD.0b013e328344c145
   PubMed Web of Science ®Google Scholar
• Gottlieb J, Janier M, Battistella M, et al. Image Gallery: lenalidomide for the treatment of pseudotumoral herpes simplex virus type 2 infection in human immunodeficiency virus infection. Br J Dermatol. 2018;178(1):e63. doi:10.1111/bjd.16041
   PubMed Web of Science ®Google Scholar
• Sun H, Gao Y, Li M, et al. Altered amyloid-β and tau proteins in neural-derived plasma exosomes in obstructive sleep apnea. Sleep Med. 2022;94:76–83. doi:10.1016/j.sleep.2022.03.021
   PubMed Web of Science ®Google Scholar
• Ding Y, Lin H, Shen W, et al. Interaction effects between HIV and aging on selective neurocognitive impairment. J Neuroimmune Pharmacol. 2017;12(4):661–669. doi:10.1007/s11481-017-9748-3
   PubMed Web of Science ®Google Scholar
• Guo Y, Li Y, Yu C, et al. Long-term effects of a social media-based intervention (Run4Love) on depressive symptoms of people living with HIV: 3-year follow-up of a randomized controlled trial. J Med Internet Res. 2022;24(6):e36809. doi:10.2196/36809
   PubMed Web of Science ®Google Scholar
• Nasreddine ZS, Phillips NA, Bédirian V, et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. doi:10.1111/j.1532-5415.2005.53221.x
   PubMed Web of Science ®Google Scholar
• Sacktor NC, Wong M, Nakasujja N, et al. The international HIV dementia scale: a new rapid screening test for HIV dementia. Aids. 2005;19(13):1367–1374.
   PubMed Web of Science ®Google Scholar
• Sereti I, Sheikh V, Shaffer D, et al. Prospective International study of incidence and predictors of immune reconstitution inflammatory syndrome and death in people living with human immunodeficiency virus and severe lymphopenia. Clin Infect Dis. 2020;71(3):652–660. doi:10.1093/cid/ciz877
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2010;50(3):291–322. doi:10.1086/649858
   PubMed Web of Science ®Google Scholar
• Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology. 2010;75(23):2087–2096. doi:10.1212/WNL.0b013e318200d727
   PubMed Web of Science ®Google Scholar
• Habib AG, Yakasai AM, Owolabi LF, et al. Neurocognitive impairment in HIV-1-infected adults in Sub-Saharan Africa: a systematic review and meta-analysis. Int J Infect Dis. 2013;17(10):e820–31. doi:10.1016/j.ijid.2013.06.011
   PubMed Web of Science ®Google Scholar
• Levine AJ, Hinkin CH, Ando K, et al. An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults. J Clin Exp Neuropsychol. 2008;30(7):836–843. doi:10.1080/13803390701819036
   PubMed Web of Science ®Google Scholar
• Saylor D. Neurologic complications of human immunodeficiency virus infection. Continuum. 2018;24(5):1397–1421. doi:10.1212/CON.0000000000000647
   PubMedGoogle Scholar
• Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–1799. doi:10.1212/01.WNL.0000287431.88658.8b
   PubMed Web of Science ®Google Scholar
• Zayyad Z, Spudich S. Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). Curr HIV/AIDS Rep. 2015;12(1):16–24. doi:10.1007/s11904-014-0255-3
   PubMed Web of Science ®Google Scholar
• Carlson RD, Rolfes MA, Birkenkamp KE, et al. Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study. Metab Brain Dis. 2014;29(2):269–279. doi:10.1007/s11011-013-9476-1
   PubMed Web of Science ®Google Scholar
• Marr KA, Sun Y, Spec A, et al. A multicenter, longitudinal cohort study of cryptococcosis in human immunodeficiency virus-negative people in the United States. Clin Infect Dis. 2020;70(2):252–261. doi:10.1093/cid/ciz193
   PubMed Web of Science ®Google Scholar
• Anjum S, Dean O, Kosa P, et al. Outcomes in previously healthy cryptococcal meningoencephalitis patients treated with pulse taper corticosteroids for post-infectious inflammatory syndrome. Clin Infect Dis. 2021;73(9):e2789–e2798. doi:10.1093/cid/ciaa1901
   PubMed Web of Science ®Google Scholar